Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

A 6 Month Safety Extension Study of MBGS205

NCT02908074
completedphase_2

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

NCT02730169
terminatedphase_2

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440

Clinical Trials (3)

Showing 3 of 3 trials
NCT02908074Phase 2

A 6 Month Safety Extension Study of MBGS205

Completed
NCT02730169Phase 2

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Completed
NCT01116440Phase 2

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3